Aveo Pharmaceuticals (AVEO) 0.92 $AVEO
The Zacks Analyst Blog Highlights: Vertex, Aurinia, AVEO and Amgen
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 8:30AM CDT
The Zacks Analyst Blog Highlights: Vertex, Aurinia, AVEO and Amgen
VRTX: 94.44 (-0.07), AUPH: 1.98 (+0.04), AVEO: 0.92 (-0.01), AMGN: 169.73 (-0.33)
Biotech Stock Roundup: Vertex Slips on Study Halt, Aurinia Plunges on Lupus Data
Arpita Dutt - Zacks Investment Research - Wed Aug 17, 2:49PM CDT
With second quarter earnings season drawing to a close, focus in back on pipeline and regulatory updates.
BIIB: 305.42 (-0.21), VRTX: 94.44 (-0.07), AUPH: 1.98 (+0.04), OGXI: 0.55 (+0.01), GILD: 77.17 (-1.21), AVEO: 0.92 (-0.01), AMGN: 169.73 (-0.33)
AVEO Initiates the Evaluation of Tivozanib in Combination with Bristol-Myers Squibb's Opdivo(R) (nivolumab) in Advanced Renal Cell Carcinoma
BusinessWire - Mon Aug 15, 6:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced the initiation of a clinical evaluation of AVEO's oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI), tivozanib, in combination with Bristol-Myers Squibb's anti-PD-1 therapy, Opdivo(R) (nivolumab), in advanced renal cell carcinoma (RCC). Bristol-Myers Squibb will supply nivolumab for use in the Phase 1/2 AVEO-sponsored TiNivo trial. The trial will be led by the Institut Gustave Roussy in Paris under the direction of Professor Bernard Escudier, MD, Chairman of the Genitourinary Oncology Committee.
AVEO: 0.92 (-0.01), BMY: 56.72 (-0.67)
AVEO (AVEO) Reports a Wider Loss in Q2, Tivozanib in Focus
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 10:04AM CDT
AVEO Pharmaceuticals (AVEO) second-quarter 2016 loss of 13 cents per share was a penny narrower than the Zacks Consensus Estimate.
GERN: 2.72 (+0.03), AVEO: 0.92 (-0.01), CORT: 5.31 (-0.02), ANIK: 47.79 (+0.55)
AVEO (AVEO) Reports Narrower-than-Expected Loss in Q2
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 8:23AM CDT
AVEO Pharmaceuticals (AVEO) posted a narrower-than-expected loss of 13 cents in the second quarter of 2016.
AVEO: 0.92 (-0.01)
AVEO Oncology Reports Second Quarter 2016 Financial Results and Provides Business Update
BusinessWire - Thu Aug 04, 6:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today reported financial results for the second quarter ended June 30, 2016.
AVEO: 0.92 (-0.01)
Will AVEO (AVEO) Pull a Surprise This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 4:58PM CDT
AVEO Pharmaceuticals (AVEO), which is expected to report second-quarter 2016 results on Aug 8, had posted in-line results last quarter.
IPXL: 23.77 (-0.42), BMRN: 94.84 (+0.95), AVEO: 0.92 (-0.01), MYL: 41.87 (-0.49)
7 Biotech Stocks that are Buys Right Now
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 10:00AM CDT
Buy these seven biotech stocks now and see how well the second half of 2016 unfolds for this industry.
MSTX: 0.54 (+0.10), RTRX: 16.26 (+0.24), AVEO: 0.92 (-0.01), SNSS: 0.84 (+0.03), LGND: 106.07 (+2.76), BIND: 0.78 (-0.09), ACOR: 24.18 (+0.10)
AVEO to Present at the 2016 JMP Securities Life Science Conference
BusinessWire - Wed Jun 15, 6:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced that Michael Needle, M.D., Chief Medical Officer, will present at the 2016 JMP Securities Life Sciences Conference on Wednesday, June 22, 2016 at 11:00 AM Eastern Time. The conference is being held at the St. Regis Hotel in New York.
AVEO: 0.92 (-0.01)
Will AVEO Pharmaceuticals (AVEO) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 4:52AM CDT
As of late, it has definitely been a great time to be an investor AVEO Pharmaceuticals, Inc. (AVEO)
AVEO: 0.92 (-0.01)
AVEO Announces Dosing of First Patient in the Pivotal Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma
BusinessWire - Thu May 26, 6:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced that the first patient has been dosed in the Company's pivotal TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC). Tivozanib is an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI).
AVEO: 0.92 (-0.01)
AVEO Announces Closing of Private Placement and Amended Term Loan to Fund Pivotal TIVO-3 Trial and Combination PD-1 Trial of Tivozanib in Renal Cell Cancer
BusinessWire - Wed May 18, 6:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced that it has closed its previously announced private placement of 17,642,482 units, consisting of one share of common stock and a warrant to purchase one share of common stock, at a price of $0.965 per unit, for gross proceeds of approximately $17 million. The transaction was led by New Enterprise Associates and included New Leaf Venture Partners and Perceptive Advisors, among other institutional investors. Certain members of the Company's management team and Board of Directors also participated in the financing.
AVEO: 0.92 (-0.01)
AVEO Announces $17 Million Private Placement
BusinessWire - Fri May 13, 8:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced that it entered into a securities purchase agreement for a private placement with a select group of qualified institutional buyers, institutional accredited investors and accredited investors. The private placement will consist of 17,642,482 units, at a price of $0.965 per unit, for gross proceeds of approximately $17 million, before deducting placement agent fees and estimated offering expenses. Each unit consists of one share of AVEO's common stock and a warrant to purchase one share of AVEO's common stock. The warrants will have an exercise price of $1.00 per share and will be exercisable for a period of five years from the date of issuance. The closing of the financing is expected to take place on or about May 18, 2016, and is subject to standard closing conditions. AVEO expects to use the proceeds from the financing to fund its U.S. pivotal Phase 3 trial of tivozanib, to support a combination trial of tivozanib with a PD-1 inhibitor and for general corporate purposes.
AVEO: 0.92 (-0.01)
AVEO Q1 Loss In Line with Expectation, Tivozanib in Focus
Zacks Equity Research - Zacks Investment Research - Wed May 11, 9:19AM CDT
AVEO Pharmaceuticals' (AVEO) first-quarter 2016 loss of 13 cents per share came in line with the Zacks Consensus Estimate.
ANIP: 61.40 (+1.66), RTRX: 16.26 (+0.24), AVEO: 0.92 (-0.01), BMY: 56.72 (-0.67)
AVEO reports 1Q loss
Automated Insights - Tue May 10, 3:13PM CDT
CAMBRIDGE, Mass. (AP) _ AVEO Pharmaceuticals Inc. (AVEO) on Tuesday reported a loss of $7.7 million in its first quarter.
AVEO: 0.92 (-0.01)
AVEO Oncology Reports First Quarter 2016 Financial Results and Provides Business Update
BusinessWire - Tue May 10, 3:01PM CDT
AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2016.
AVEO: 0.92 (-0.01)
Drug Stocks Earnings Preview: GERN, RPRX, ICPT, AGIO & More
Zacks Equity Research - Zacks Investment Research - Wed May 04, 10:25AM CDT
As we approach the end of this earnings season, investors will possibly heave a sigh of relief seeing that the going was not as bad as expected.
ABT: 42.17 (+0.15), BIIB: 305.42 (-0.21), CNAT: 1.86 (+0.05), AMGN: 169.73 (-0.33), RPRX: 2.00 (-0.03), JNJ: 118.87 (-0.47), GILD: 77.17 (-1.21), GWPH: 81.92 (+0.17), GERN: 2.72 (+0.03), AVEO: 0.92 (-0.01), ICPT: 146.82 (-1.49), AGIO: 36.50 (-0.34), NVS: 78.23 (-0.54)
Will AVEO Pharmaceuticals (AVEO) Surprise in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 5:42PM CDT
AVEO Pharmaceuticals (AVEO) is expected to report first-quarter 2016 results on Mar 5.
ZTS: 50.84 (-0.26), OPHT: 52.54 (-0.27), AVEO: 0.92 (-0.01), NVS: 78.23 (-0.54)
AVEO Announces Filing of Provisional Patent Applications for AV-353, a Notch 3-Specific Inhibitor Antibody for PAH
BusinessWire - Mon May 02, 6:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced that it has filed provisional patent applications with the United States Patent and Trademark Office (USPTO) covering composition of matter claims for AV-353, the Company's potent inhibitory antibody specific to Notch 3. These patent applications are the second set of applications related to AV-353 and the Company's Notch 3 antibody program.
AVEO: 0.92 (-0.01)
AVEO Gives AV-203 Ex-U.S. Rights to CANbridge Life Sciences
Zacks Equity Research - Zacks Investment Research - Wed Mar 23, 3:25AM CDT
AVEO Pharmaceuticals (AVEO) struck an exclusive collaboration and license agreement granting CANbridge Life Sciences rights to AV-203 outside North America.
BIIB: 305.42 (-0.21), OPHT: 52.54 (-0.27), AVEO: 0.92 (-0.01), NVS: 78.23 (-0.54)
The Zacks Analyst Blog Highlights: Vertex, Aurinia, AVEO and Amgen
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 8:30AM CDT
The Zacks Analyst Blog Highlights: Vertex, Aurinia, AVEO and Amgen
VRTX: 94.44 (-0.07), AUPH: 1.98 (+0.04), AVEO: 0.92 (-0.01), AMGN: 169.73 (-0.33)
Biotech Stock Roundup: Vertex Slips on Study Halt, Aurinia Plunges on Lupus Data
Arpita Dutt - Zacks Investment Research - Wed Aug 17, 2:49PM CDT
With second quarter earnings season drawing to a close, focus in back on pipeline and regulatory updates.
BIIB: 305.42 (-0.21), VRTX: 94.44 (-0.07), AUPH: 1.98 (+0.04), OGXI: 0.55 (+0.01), GILD: 77.17 (-1.21), AVEO: 0.92 (-0.01), AMGN: 169.73 (-0.33)
AVEO Initiates the Evaluation of Tivozanib in Combination with Bristol-Myers Squibb's Opdivo(R) (nivolumab) in Advanced Renal Cell Carcinoma
BusinessWire - Mon Aug 15, 6:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced the initiation of a clinical evaluation of AVEO's oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI), tivozanib, in combination with Bristol-Myers Squibb's anti-PD-1 therapy, Opdivo(R) (nivolumab), in advanced renal cell carcinoma (RCC). Bristol-Myers Squibb will supply nivolumab for use in the Phase 1/2 AVEO-sponsored TiNivo trial. The trial will be led by the Institut Gustave Roussy in Paris under the direction of Professor Bernard Escudier, MD, Chairman of the Genitourinary Oncology Committee.
AVEO: 0.92 (-0.01), BMY: 56.72 (-0.67)
AVEO (AVEO) Reports a Wider Loss in Q2, Tivozanib in Focus
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 10:04AM CDT
AVEO Pharmaceuticals (AVEO) second-quarter 2016 loss of 13 cents per share was a penny narrower than the Zacks Consensus Estimate.
GERN: 2.72 (+0.03), AVEO: 0.92 (-0.01), CORT: 5.31 (-0.02), ANIK: 47.79 (+0.55)
AVEO (AVEO) Reports Narrower-than-Expected Loss in Q2
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 8:23AM CDT
AVEO Pharmaceuticals (AVEO) posted a narrower-than-expected loss of 13 cents in the second quarter of 2016.
AVEO: 0.92 (-0.01)
AVEO Oncology Reports Second Quarter 2016 Financial Results and Provides Business Update
BusinessWire - Thu Aug 04, 6:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today reported financial results for the second quarter ended June 30, 2016.
AVEO: 0.92 (-0.01)
Will AVEO (AVEO) Pull a Surprise This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 4:58PM CDT
AVEO Pharmaceuticals (AVEO), which is expected to report second-quarter 2016 results on Aug 8, had posted in-line results last quarter.
IPXL: 23.77 (-0.42), BMRN: 94.84 (+0.95), AVEO: 0.92 (-0.01), MYL: 41.87 (-0.49)
7 Biotech Stocks that are Buys Right Now
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 10:00AM CDT
Buy these seven biotech stocks now and see how well the second half of 2016 unfolds for this industry.
MSTX: 0.54 (+0.10), RTRX: 16.26 (+0.24), AVEO: 0.92 (-0.01), SNSS: 0.84 (+0.03), LGND: 106.07 (+2.76), BIND: 0.78 (-0.09), ACOR: 24.18 (+0.10)
AVEO to Present at the 2016 JMP Securities Life Science Conference
BusinessWire - Wed Jun 15, 6:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced that Michael Needle, M.D., Chief Medical Officer, will present at the 2016 JMP Securities Life Sciences Conference on Wednesday, June 22, 2016 at 11:00 AM Eastern Time. The conference is being held at the St. Regis Hotel in New York.
AVEO: 0.92 (-0.01)
Will AVEO Pharmaceuticals (AVEO) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 4:52AM CDT
As of late, it has definitely been a great time to be an investor AVEO Pharmaceuticals, Inc. (AVEO)
AVEO: 0.92 (-0.01)
AVEO Announces Dosing of First Patient in the Pivotal Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma
BusinessWire - Thu May 26, 6:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced that the first patient has been dosed in the Company's pivotal TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC). Tivozanib is an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI).
AVEO: 0.92 (-0.01)
AVEO Announces Closing of Private Placement and Amended Term Loan to Fund Pivotal TIVO-3 Trial and Combination PD-1 Trial of Tivozanib in Renal Cell Cancer
BusinessWire - Wed May 18, 6:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced that it has closed its previously announced private placement of 17,642,482 units, consisting of one share of common stock and a warrant to purchase one share of common stock, at a price of $0.965 per unit, for gross proceeds of approximately $17 million. The transaction was led by New Enterprise Associates and included New Leaf Venture Partners and Perceptive Advisors, among other institutional investors. Certain members of the Company's management team and Board of Directors also participated in the financing.
AVEO: 0.92 (-0.01)
AVEO Announces $17 Million Private Placement
BusinessWire - Fri May 13, 8:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced that it entered into a securities purchase agreement for a private placement with a select group of qualified institutional buyers, institutional accredited investors and accredited investors. The private placement will consist of 17,642,482 units, at a price of $0.965 per unit, for gross proceeds of approximately $17 million, before deducting placement agent fees and estimated offering expenses. Each unit consists of one share of AVEO's common stock and a warrant to purchase one share of AVEO's common stock. The warrants will have an exercise price of $1.00 per share and will be exercisable for a period of five years from the date of issuance. The closing of the financing is expected to take place on or about May 18, 2016, and is subject to standard closing conditions. AVEO expects to use the proceeds from the financing to fund its U.S. pivotal Phase 3 trial of tivozanib, to support a combination trial of tivozanib with a PD-1 inhibitor and for general corporate purposes.
AVEO: 0.92 (-0.01)
AVEO Q1 Loss In Line with Expectation, Tivozanib in Focus
Zacks Equity Research - Zacks Investment Research - Wed May 11, 9:19AM CDT
AVEO Pharmaceuticals' (AVEO) first-quarter 2016 loss of 13 cents per share came in line with the Zacks Consensus Estimate.
ANIP: 61.40 (+1.66), RTRX: 16.26 (+0.24), AVEO: 0.92 (-0.01), BMY: 56.72 (-0.67)
AVEO reports 1Q loss
Automated Insights - Tue May 10, 3:13PM CDT
CAMBRIDGE, Mass. (AP) _ AVEO Pharmaceuticals Inc. (AVEO) on Tuesday reported a loss of $7.7 million in its first quarter.
AVEO: 0.92 (-0.01)
AVEO Oncology Reports First Quarter 2016 Financial Results and Provides Business Update
BusinessWire - Tue May 10, 3:01PM CDT
AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2016.
AVEO: 0.92 (-0.01)
Drug Stocks Earnings Preview: GERN, RPRX, ICPT, AGIO & More
Zacks Equity Research - Zacks Investment Research - Wed May 04, 10:25AM CDT
As we approach the end of this earnings season, investors will possibly heave a sigh of relief seeing that the going was not as bad as expected.
ABT: 42.17 (+0.15), BIIB: 305.42 (-0.21), CNAT: 1.86 (+0.05), AMGN: 169.73 (-0.33), RPRX: 2.00 (-0.03), JNJ: 118.87 (-0.47), GILD: 77.17 (-1.21), GWPH: 81.92 (+0.17), GERN: 2.72 (+0.03), AVEO: 0.92 (-0.01), ICPT: 146.82 (-1.49), AGIO: 36.50 (-0.34), NVS: 78.23 (-0.54)
Will AVEO Pharmaceuticals (AVEO) Surprise in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 5:42PM CDT
AVEO Pharmaceuticals (AVEO) is expected to report first-quarter 2016 results on Mar 5.
ZTS: 50.84 (-0.26), OPHT: 52.54 (-0.27), AVEO: 0.92 (-0.01), NVS: 78.23 (-0.54)
AVEO Announces Filing of Provisional Patent Applications for AV-353, a Notch 3-Specific Inhibitor Antibody for PAH
BusinessWire - Mon May 02, 6:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced that it has filed provisional patent applications with the United States Patent and Trademark Office (USPTO) covering composition of matter claims for AV-353, the Company's potent inhibitory antibody specific to Notch 3. These patent applications are the second set of applications related to AV-353 and the Company's Notch 3 antibody program.
AVEO: 0.92 (-0.01)
AVEO Gives AV-203 Ex-U.S. Rights to CANbridge Life Sciences
Zacks Equity Research - Zacks Investment Research - Wed Mar 23, 3:25AM CDT
AVEO Pharmaceuticals (AVEO) struck an exclusive collaboration and license agreement granting CANbridge Life Sciences rights to AV-203 outside North America.
BIIB: 305.42 (-0.21), OPHT: 52.54 (-0.27), AVEO: 0.92 (-0.01), NVS: 78.23 (-0.54)
